- $35.98m
- -$53.64m
- $19.89m
Generation Bio Co expected to post a loss of 50 cents a share - Earnings Preview
Generation Bio Co reports results for the quarter ended in March - Earnings Summary
Brief: Generation Bio Reports First Quarter 2023 Financial Results
Brief: Generation Bio posts Q1 EPS USD -0.53
Generation Bio Co expected to post a loss of 46 cents a share - Earnings Preview
Brief: Generation Bio Appoints Yalonda Howze As Chief Legal Officer
U.S. STOCKS ON THE MOVE-Manchester United, Verona Pharma, 89Bio
U.S. STOCKS ON THE MOVE-Ollie, Commercial Metals, Copper Aluminum miners
Generation Bio climbs on licensing deal with Moderna for Genetic Medicines
Moderna, Generation Bio enter licensing deal for genetic medicines (updated)
Brief: Moderna And Generation Bio Announce Strategic Collaboration To Develop Non-Viral Genetic Medicines
Brief: Generation Bio-Eligible To Get Up To $1.8 Billion In Milestone Payments Upon Achievement Of Specified Development, Regulatory, Commercial Milestone Events
Moderna strikes licensing deal with Generation Bio for genetic medicines
Currently Maintains A De Minimis Amount Of Cash And Cash Equivalents, In Mid-Single-Digit Millions Of U.S. Dollars, With Svb
Expects To Announce Data For Factor Viii Expression In Non-Human Primates In 2023
Brief: Generation Bio Outlines 2023 Strategic Priorities And Reports Fourth Quarter And Full Year 2022 Financial Results
Generation Bio Co reports results for the quarter ended in December - Earnings Summary
Generation Bio Co expected to post a loss of 58 cents a share - Earnings Preview
Generation Bio Co reports results for the quarter ended in September - Earnings Summary